Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biosimilar entities : Abbvie inc. save search
Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances
Published: 2024-02-14 (Crawled : 20:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.26%
H: 0.87%
C: 0.32%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.48%
H: 1.56%
C: 1.48%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.75%
H: 0.86%
C: 0.41%
biosimilar report global therapy growth market
Celltrion Healthcare announces the availability of Yuflyma a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.03%
H: 0.08%
C: -2.9%
humira biosimilar canada
Settlement Opens Doors for Biosimilars of Abbvie's Most Profitable Drug
Published: 2022-03-09 (Crawled : 15:30) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
drug set biosimilar
Celltrion Healthcare announces Canadian approval of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
health thc approval cel humira biosimilar
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Published: 2022-01-05 (Crawled : 16:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.32%
H: 3.3%
C: 2.1%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
humira fda fda acceptance biosimilar
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
Published: 2021-10-01 (Crawled : 20:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
fda biosimilar
Alvotech Announces Positive Top-Line Results for Switching Study Between Proposed Biosimilar AVT02 and Humira®
Published: 2021-09-09 (Crawled : 22:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.83%
H: 0.27%
C: -1.98%
positive results topline biosimilar
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.